Castle Biosciences vs Grail
Castle Biosciences reported revenue of $344 million in fiscal 2025, 2.3 times Grail's $147 million in fiscal 2025. Castle Biosciences' revenue grew 3.7% in its latest year, and Grail's grew 17.2%. Castle Biosciences had an operating margin of -12.4%, against -382.0% at Grail. Free cash flow was $28 million at Castle Biosciences and −$300 million at Grail.
Side by side
| Castle Biosciences | Grail | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $344M | $147M |
| Revenue growth | 3.7% | 17.2% |
| Revenue growth a year, last 5 years | 40.6% | — |
| Gross margin | 79.4% | — |
| Operating margin | −12.4% | −382.0% |
| Net margin | −7.0% | −277.5% |
| Free cash flow | $28M | −$300M |
| Free cash flow margin | 8.2% | −203.8% |
| Return on capital | −19.1% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | −0.9% | 15.2% |
| Last close | $33.79 | $115.89 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | sold $110.6 million |
| Piotroski F-score | 4 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Castle BiosciencesGrail
Operating margin
Percent of revenue
Castle BiosciencesGrail
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Castle BiosciencesGrail
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Castle Biosciences and Grail pages.